Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO Brian M. Strem, Ph.D., will deliver a presentation updating investors on the company's pipeline developments.
The presentation will focus on two key clinical trials: the planned Phase 2 trials of KIO-104 for retinal inflammation treatment and KIO-301 for retinitis pigmentosa treatment. Investors can access the live presentation through Kiora's investor relations website (ir.kiorapharma.com), with replay available for 90 days on the events page.
Kiora Pharmaceuticals (NASDAQ: KPRX) ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale sulla Sanità di Needham giovedì 10 aprile 2025, alle 14:15 EDT. Il Presidente e CEO Brian M. Strem, Ph.D. presenterà un aggiornamento agli investitori sui progressi della pipeline dell'azienda.
La presentazione si concentrerà su due trial clinici chiave: i trial di Fase 2 pianificati per KIO-104 per il trattamento dell'infiammazione retinica e KIO-301 per il trattamento della retinite pigmentosa. Gli investitori possono accedere alla presentazione dal vivo attraverso il sito web delle relazioni con gli investitori di Kiora (ir.kiorapharma.com), con una registrazione disponibile per 90 giorni nella pagina degli eventi.
Kiora Pharmaceuticals (NASDAQ: KPRX) ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham el jueves 10 de abril de 2025, a las 2:15 p.m. EDT. El Presidente y CEO Brian M. Strem, Ph.D. ofrecerá una presentación actualizando a los inversores sobre los desarrollos de la cartera de la empresa.
La presentación se centrará en dos ensayos clínicos clave: los ensayos de Fase 2 planificados para KIO-104 para el tratamiento de la inflamación retinal y KIO-301 para el tratamiento de la retinitis pigmentosa. Los inversores pueden acceder a la presentación en vivo a través del sitio web de relaciones con inversores de Kiora (ir.kiorapharma.com), con una repetición disponible durante 90 días en la página de eventos.
Kiora Pharmaceuticals (NASDAQ: KPRX)는 2025년 4월 10일 목요일 오후 2시 15분 EDT에 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 사장 겸 CEO 브라이언 M. 스트렘 박사가 회사의 파이프라인 개발에 대한 업데이트를 투자자들에게 발표할 예정입니다.
이번 발표는 두 가지 주요 임상 시험에 초점을 맞출 것입니다: 망막 염증 치료를 위한 KIO-104의 계획된 2상 시험과 망막색소변성증 치료를 위한 KIO-301입니다. 투자자들은 Kiora의 투자자 관계 웹사이트(ir.kiorapharma.com)를 통해 실시간 발표에 접근할 수 있으며, 이벤트 페이지에서 90일 동안 재생할 수 있습니다.
Kiora Pharmaceuticals (NASDAQ: KPRX) a annoncé sa participation à la 24e Conférence Virtuelle Annuelle sur la Santé de Needham le jeudi 10 avril 2025, à 14h15 EDT. Le Président et CEO Brian M. Strem, Ph.D. présentera une mise à jour aux investisseurs sur les développements de la pipeline de l'entreprise.
La présentation se concentrera sur deux essais cliniques clés : les essais de Phase 2 prévus pour KIO-104 pour le traitement de l'inflammation rétinienne et KIO-301 pour le traitement de la rétinite pigmentaire. Les investisseurs peuvent accéder à la présentation en direct via le site web des relations investisseurs de Kiora (ir.kiorapharma.com), avec une rediffusion disponible pendant 90 jours sur la page des événements.
Kiora Pharmaceuticals (NASDAQ: KPRX) hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham am Donnerstag, den 10. April 2025, um 14:15 Uhr EDT bekannt gegeben. Präsident & CEO Brian M. Strem, Ph.D. wird eine Präsentation halten, um die Investoren über die Entwicklungen in der Pipeline des Unternehmens zu informieren.
Die Präsentation wird sich auf zwei wichtige klinische Studien konzentrieren: die geplanten Phase-2-Studien zu KIO-104 zur Behandlung von retinaler Entzündung und KIO-301 zur Behandlung von Retinitis pigmentosa. Investoren können die Live-Präsentation über die Investor-Relations-Website von Kiora (ir.kiorapharma.com) abrufen, mit einer Wiederholung, die 90 Tage lang auf der Veranstaltungsseite verfügbar ist.
- None.
- None.
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT.
President & CEO, Brian M. Strem, Ph.D., will provide an update on the progress of the Company's pipeline and its planned Phase 2 clinical trials of KIO-104 for the treatment of retinal inflammation and of KIO-301 for the treatment of retinitis pigmentosa.
The presentation may be accessed live from the homepage of the investor relations section (ir.kiorapharma.com) of Kiora's website and will be available for replay for 90 days on the investor relations "events" page (ir.kiorapharma.com/news-events/events).
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn, as well as to visit our website and/or subscribe to email alerts.
Contacts:
Investors
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247286
FAQ
When is Kiora Pharmaceuticals (KPRX) presenting at the Needham Healthcare Conference 2025?
What clinical trials will KPRX discuss at the Needham Conference 2025?
How can investors access KPRX's Needham Conference presentation?
What pipeline updates will KPRX present at the Needham Healthcare Conference?
